Neuberger Berman Group LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Neuberger Berman Group LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$83.14 - $145.99 $51,463 - $90,367	619 Added 31.6%	2,578 $375,000
Q1 2022 May 13, 2022	BUY	$110.08 - $142.92 $2,752 - $3,572	25 Added 1.29%	1,959 $210,000
Q4 2021 Feb 11, 2022	BUY	$99.73 - $148.48 $192,877 - $287,160	1,934 New	1,934 $241,000
Q1 2021 May 13, 2021	SELL	$64.07 - $91.75 $1.41 Million - $2.02 Million	-22,045 Closed	0 $0
Q4 2020 Feb 10, 2021	SELL	$65.07 - $98.24 $29,606 - $44,699	-455 Reduced 2.02%	22,045 $1.89 Million
Q4 2019 Feb 12, 2020	SELL	$40.86 - $57.65 $715,050 - $1.01 Million	-17,500 Reduced 43.75%	22,500 $1.23 Million
Q3 2019 Nov 13, 2019	SELL	$37.38 - $49.47 $280,350 - $371,025	-7,500 Reduced 15.79%	40,000 $1.67 Million
Q2 2019 Aug 13, 2019	BUY	$39.79 - $67.01 $875,380 - $1.47 Million	22,000 Added 86.27%	47,500 $2.08 Million
Q1 2019 May 13, 2019	BUY	$34.52 - $53.29 $535,060 - $825,995	15,500 Added 155.0%	25,500 $1.31 Million
Q4 2018 Feb 12, 2019	BUY	$29.75 - $42.9 $297,500 - $429,000	10,000 New	10,000 $370,000

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.